



February 1, 2013

Company Name 3 - D Matrix, Ltd.  
Address 3-2-4, Kojimachi, Chiyoda, Tokyo  
President Kentaro Takamura  
Code Number 7777  
Contact Director Tomoyuki Arai  
TEL +81 3 (3511)3440

### Revision of Forecast of Financial Results for FY2012

The company hereby announces a revision of forecast of financial results for FY2012 (May 1, 2012 to April 30, 2013) which was previously announced on June 13, 2012.

1. Revision of forecast of financial results for FY2012 (May 1, 2012 to April 30, 2013)

[Consolidated]

(Millions of yen, %)

	Operating revenue	Operating income	Ordinary income	Net income	Net income per share
Forecast announced previously (A)	2,491	589	583	529	Yen 57.47
<b>Revised forecast (B)</b>	<b>1,850</b>	<b>152</b>	<b>160</b>	<b>130</b>	<b>14.10</b>
Change (B-A)	-641	-437	-423	-398	—
Change (%)	-25.8	-74.2	-72.5	-75.4	—
Reference: Previous year results (FY2011)	1,107	354	309	308	36.85

[Non-consolidated]

(Millions of yen, %)

	Operating revenue	Operating income	Ordinary income	Net income	Net income per share
Forecast announced previously (A)	2,491	911	905	851	Yen 92.47
<b>Revised forecast (B)</b>	<b>1,850</b>	<b>438</b>	<b>441</b>	<b>411</b>	<b>44.50</b>
Change (B-A)	-641	-472	-464	-440	—
Change (%)	-25.8	-51.9	-51.3	-51.7	—
Reference: Previous year results (FY2011)	1,107	432	386	385	46.05

Note: The performance forecast was prepared based on information obtained as of the time of announcement. Actual results may differ significantly from the forecast due to various subsequent factors.

Note: The common stock of the company underwent a stock split of 2 to 1 on September 1, 2012. Net income per share for FY2011 has been adjusted to reflect this stock split.

2. Reasons of revision (for both consolidated and non-consolidated financial results)

The company's first pipeline, hemostat (TDM-621) is currently under review by the Pharmaceuticals and Medical Devices Agency, Japan (PMDA) for manufacturing and marketing approval, application submitted to PMDA in May, 2011. As it is taking longer than anticipated to obtain this approval, business progress originally budgeted for FY2012, including listing for insurance reimbursement and approval for manufacturing and marketing in Korea and Taiwan, is likely to be postponed to FY2013.

Therefore, milestone payments resulting from this business progress will be received in FY2013 rather than FY2012, and the previously forecasted operating revenue of ¥2,491 million is revised downward to ¥1,850 million.

Operating income is also revised downward primarily because of the operating revenue decrease, despite our continued effort to reduce costs including subcontracting fees.

As a result, our revised forecast consolidated operating revenue for FY2012 is ¥152 million (down ¥437 million from previous forecast), with ordinary income of ¥160 million (down ¥423 million) and net income of ¥130 million (down ¥398 million). Similarly for non-consolidated results, operating revenue of ¥438 million (down ¥472 million), ordinary income of ¥441 million (down ¥464 million), and net income of ¥411 million (down ¥440 million) are the revised estimates.

[For reference]

Revision of mid-term business plan (consolidated)

This revision of results is due to the milestone payments being received in the next fiscal year, and the company's mid-term business plan that reflects this change is as follows. For details, please refer to our notification "Revision of mid-term business plan" also announced on the same date.

(Millions of yen)

	Operating revenue	Operating income	Ordinary income	Net income
FY2012 (forecast)	1,850	152	160	130
FY2013 (target)	4,495	1,691	1,685	1,441
FY2014 (target)	8,006	3,521	3,515	2,222

Note: Figures above are extracted from the company's revised mid-term business plan announced on February 1, 2013.

Note: The performance forecast was prepared based on information obtained as of the time of announcement. Actual results may differ significantly from the forecast due to various subsequent factors.